Cloning and DNA-binding properties of the rat pancreatic β-cell-specific factor Nkx6.1  by Jørgensen, Mette Christine et al.
Cloning and DNA-binding properties of the rat pancreatic L-cell-speci¢c
factor Nkx6.1
Mette Christine JÖrgensena, Helle Vestergafird Petersena, Johan Ericsonb,
Ole Dragsb×k Madsena, Palle Serupa;*
aDepartment of Developmental Biology, Hagedorn Research Institute, Niels Steensensvej 6, DK-2820 Gentofte, Denmark
bDepartment of Cell and Molecular Biology, Karolinska Institute, Doktorsringen 2D, S-17177 Stockholm, Sweden
Received 25 September 1999
Abstract The homeodomain (HD) protein Nkx6.1 is the most
L-cell-specific transcription factor known in the pancreas and its
function is critical for the formation of the insulin-producing L-
cells. However, the target genes, DNA-binding site, and
transcriptional properties of Nkx6.1 are unknown. Using in
vitro binding site selection we have identified the DNA sequence
of the Nkx6.1 binding site to be TTAATTG/A. A reporter
plasmid containing four copies of this sequence is activated by an
Nkx6.1HD/VP16 fusion construct. Full-length Nkx6.1 fails to
activate this reporter plasmid in spite of robust interaction with
the binding site in vitro. Stable expression of Nkx6.1 in the
glucagon-producing K-cell-like MSL-G-AN cells induces expres-
sion of the endogenous insulin gene in a subset of the cell
population. The expression of other known L-cell-specific factors
such as Pax4, Pax6, Pdx1, GLUT2 and GLP1-R is unchanged
by the introduction of Nkx6.1.
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1. Introduction
The homeodomain protein Nkx6.1 was originally identi¢ed
in a screen for new pancreatic islet cell homeobox genes by
degenerate PCR using a HIT (hamster insulinoma) cDNA
library [1]. During rat embryonic development, Nkx6.1 is de-
tected in almost all of the nuclei of the epithelial cells in both
of the pancreatic buds. Early endocrine cells are devoid of
Nkx6.1 while later, mature insulin-producing L-cells display
a strong nuclear Nkx6.1 immunoreactivity [2]. In the newborn
rat pancreas, Nkx6.1 expression is restricted to the nuclei of
the L-cells of the islets. Additionally, Nkx6.1 is expressed in
the antral part of the stomach [3,4]. Furthermore, studies in
mouse and chick embryos have shown that Nkx6.1 is ex-
pressed in the central nervous system (CNS) during develop-
ment where it is found in the ventral part of the neural tube
with a clear anterior boundary near the zona limitans intra-
thalamica [5]. This restricted expression pattern of Nkx6.1
suggests that Nkx6.1 is necessary for proper L-cell formation
and CNS development. Nkx6.1 belongs to the NK family of
homeodomain transcription factors even though the relation-
ship to the majority of the family members is weak. The
closest relative is Nkx6.2 (also called Gtx, glial- and testis-
speci¢c homeobox gene) [6], which shares an overall 67.5%
sequence identity with Nkx6.1. The long alanine and serine
stretches found in the N-terminal part of Nkx6.1 are absent in
Nkx6.2, whereas the homeodomains are 95% identical (only
three residues di¡er). The gene products of more thoroughly
characterised NK family members appear to be involved in
speci¢cation of cell fate and di¡erentiation in speci¢c tissues.
This is exempli¢ed by Nkx2.1 (also known as TTF1 and T/
EBP), which is required for proper development of the thy-
roid, lungs, and the basal plate of the forebrain [7], and
Nkx2.2 which is required for proper patterning of the neural
tube [8] and for the di¡erentiation of completely matured
pancreatic L-cells [9].
Little is known about the control of Nkx6.1 expression. In
mice where the Pdx1 gene was speci¢cally inactivated in the L-
cells, Nkx6.1 could not be detected in the pancreatic islets
[10]. Similarly, Nkx2.2-de¢cient mice show a complete lack
of Nkx6.1 in the islet L-cells, which also lack insulin expres-
sion [9]. In mature L-cells, Nkx6.1 expression seems to require
the presence of both Pdx1 and Nkx2.2. However, nothing is
yet known about target genes downstream of Nkx6.1.
To begin to address the function of Nkx6.1, we have iso-
lated the rat Nkx6.1 cDNA sequence and determined the op-
timal DNA-binding site of the protein. A reporter plasmid
with four copies of the Nkx6.1-binding site inserted in front
of a TK promoter was activated by an Nkx6.1HD/VP16AD
fusion protein. In an attempt to discover target genes for
Nkx6.1, we have stably transfected MSL-G-AN glucagonoma
cells with an Nkx6.1 cDNA and studied the expression of
multiple L-cell-speci¢c genes in the resulting clones.
2. Materials and methods
2.1. Screening of cDNA library
A 220 bp sequence fragment of Nkx6.1 was PCR ampli¢ed from rat
islet cDNA using the hamster Nkx6.1 primers 5P-TCCCGGGAATT-
CATGGCCACCGCCAAGAAGAAGCAG-3P (sense) and 5P-GCG-
GGCGGGCGGCCGCCGCTCAGGACGAGCCCTCGG-3P (anti-
sense) containing the restriction sites for EaeI and NotI,
respectively. The fragment was cut with EaeI and NotI and inserted
at the NotI site of pBluescript SK II from Stratagene. The correct
identity of the insert was veri¢ed by sequencing and used as the
Nkx6.1 speci¢c probe. It was 32P-labeled with Klenow and random
priming using the RPN 1601Y Multiprime DNA labeling system from
Amersham. A high stringency colony hybridisation screening of 105
cfu was performed essentially as described in [11] on a newborn rat
islet cDNA library [12].
2.2. Sequencing of rat Nkx6.1 cDNA
The 3.2 kb rat Nkx6.1 cDNA sequence was obtained by primer
walking and was carried out doing cycle sequencing PCR using the
fmol DNA Sequencing System from Promega or Thermo Sequenase
from Amersham. The reactions were separated on 5% polyacrylamide
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sequencing gels with 8.3 M urea in 1UTBE. Both strands of the
coding region were sequenced, whereas the untranslated regions
(UTRs) were only sequenced in one direction.
2.3. In vitro translation
The 3211 bp Nkx6.1 cDNA sequence was inserted in the XbaI site
of the pBK-RSV vector from Stratagene. In vitro transcription and
translation of Nkx6.1 was carried out using the TNT Lysate Coupled
Transcription/Translation System from Promega with the T3 RNA
polymerase and in the presence of [35S]methionine. The samples
were analysed on SDS-PAGE and autoradiographed.
2.4. Expression of Nkx6.1 in COS7 cells
The 3211 bp Nkx6.1 cDNA sequence was inserted in the XbaI site
of the pCMV4 vector [13]. 3.5U105 COS7 cells were mixed with 1 Wg
pCMV4-Nkx6.1 (3.2 kb) or 1 Wg pCMV4 control vector and trans-
fected by electroporation at 700 V for 90 Ws with a 0.2 cm electrode
gap using an Electro Square Porator T820 from BTX Electroporation
Systems. The cells were allowed to recover for 24 h and then resus-
pended in 150 Wl lysis bu¡er containing 20 mM imidazole-HCl pH 6.8,
100 mM KCl, 1 mM MgCl2, 10 mM EGTA, 0.2% Triton X-100 and
1 mM AEBSF. Incubation for 5 min at room temperature and
centrifugation for 5 min at 14 000Ug gave a crude protein extract
preparation of the transfected COS7 cells. Western blot analysis was
performed as described [14].
2.5. GST-Nkx6.1HD fusion protein
The GST-Nkx6.1HD fusion protein was generated using the GST
Gene Fusion System from Pharmacia. The Nkx6.1 homeobox se-
quence (including V20 bp of £anking sequence at both sides) was
PCR ampli¢ed with the primers 5P-CAAGAATTCATTTTGTTGGA-
CAAAGATG-3P (sense) and 5P-CTTCTCGAGGGTGGCCATCTC-
GGCT-3P (antisense) containing an EcoRI and a XhoI site, respec-
tively. The product was digested with EcoRI and XhoI and ligated
into the expression vector pGEX-4T-1 at the EcoRI and XhoI sites so
that the Nkx6.1 homeobox sequence was fused in frame to the 3P-end
of the glutathione S-transferase (GST) gene. Both strands of the insert
were sequenced to ensure that no PCR-generated mutations were in-
corporated. The GST-Nkx6.1HD fusion protein was synthesised in
the protease-de¢cient Escherichia coli BL21 strain and puri¢ed on a
glutathione Sepharose 4B column according to the manufacturer’s
manual.
2.6. Electromobility shift assays (EMSAs)
The reactions were carried out at 4‡C in an EMSA bu¡er with a
¢nal concentration of 20% glycerol, 25 mM Tris-HCl pH 7.5, 150 mM
KCl, 60 mM NaCl, 2 mM MgCl2 and 1 mM DTT. Assays with
nuclear extracts from cells were added 1 Wg poly(dIdC) and 1 Wg
poly(dGdC), and assays with GST-Nkx6.1HD fusion protein were
added 0.5 Wg poly(dIdC), 0.5 Wg poly(dGdC) and 1 Wg bovine serum
albumin (BSA). When antisera were used for supershifts, 1 Wl undi-
luted antiserum was added. Between 0.02 and 2 pmol 32P-labeled
probe was added and incubated for 10 min at 4‡C. Protein-DNA
complexes were separated from unbound probe by 4 h electrophoresis
on a 6% native polyacrylamide gel at 180 V and 4‡C in 0.5UTBE
bu¡er. The A45.A probe was generated from oligo A45.A: 5P-
GAAGATCTCATTTAATTGGTTTTTAATTGGATCCGAGACTG-
AGCG-3P (the two Nkx6.1 binding sites are underlined) and 32P-phos-
phorylated antisense primer BSS3.A: 5P-CGCTCAGTCTCGGAT-
CC-3P and the complementary strand was ¢lled out with Klenow.
PCR probes were generated as described below.
2.7. Binding site selection
The Nkx6.1-binding site was determined in two independent experi-
ments performed in parallel. A synthetic randomised (N20) oligonu-
cleotide probe was generated from oligo BSS1: 5P-CGGGCTGAGA-
TCAGTCTAGATCTNNNNNNNNNNNNNNNNNNNNGGATC-
CGAGACTGAGCGTCGTC-3P and 32P-phosphorylated antisense
primer BSS3: 5P-GACGACGCTCAGTCTCGGATCC-3P and the
complementary strand was ¢lled out with Klenow. The binding
reaction was carried out in 25 Wl with 7 nM 32P-labeled (N20) oligo-
nucleotide probe in EMSA bu¡er with 0.5 Wg poly(dIdC), 0.5 Wg poly-
(dGdC), 1 Wg BSA, and 25 nM GST-Nkx6.1HD. The samples
were incubated for 15 min at 4‡C and separated on a 6% EMSA
gel. Bound oligonucleotides were excised from the undried gel and
one ¢fth was used directly in a PCR reaction to amplify the selected
sequences. The PCR reaction was carried out in 50 Wl (45 Wl+the gel
piece) with 20 pmol sense primer BSS2: 5P-CGGGCTGAGAT-
CAGTCTAGATCT-3P, 20 pmol 32P-phosphorylated antisense primer
BSS3, 250 nM dNTPs, 2 units of DynaZyme II DNA polymerase
from Finnzymes Oy and the bu¡er recommended by the manufac-
turer. The PCR conditions were 3 min at 95‡C followed by 20 cycles
of 50 s at 95‡C, 50 s at 64‡C, 1 min at 72‡C. A binding reaction was
carried out as described above with 5 Wl of the PCR reaction as probe.
The binding site selection and ampli¢cation procedure was repeated
¢ve times. The resulting selected sequences of the ¢nal PCR were
phosphorylated and cloned in a blunt ended pBluescript SK II vec-
tor from Stratagene. Forty-eight clones from each experiment were
sequenced using a 33P-labeled T7 primer and Thermo Sequenase from
Amersham.
2.8. Transient transfection of NIH-3T3 cells
The Nkx6.1HD/VP16AD fusion construct was excised from RCAS-
rNkx6.1-Homeo-VP16 by a ClaI digest and transferred to the ClaI
site of pCMV4 [13]. The construction of RCAS-rNkx6.1-Homeo-
VP16 will be described elsewhere. The reporter constructs have a
pGL3-basic (from Promega) backbone with the 754 bp thymidine
kinase (TK) promoter inserted in the BglII and the HindII sites up-
stream of the luciferase reporter gene. The oligo probe A45.A, which
contain two Nkx6.1-binding sites and a BglII and a BamHI site at the
ends, was made double-stranded with the BSS3.A antisense primer
and Klenow. The ends were cut with BglII and BamHI and two copies
were inserted at the conserved BglII site upstream of the TK promoter
of the vector. As a control a similar reporter construct was generated
with the oligo probe A45.B: 5P-GAAGATCTCATTTCCTTGGTT-
TTTCCTTGGATCCGAGACTGAGCG-3P, where the two Nkx6.1-
binding sites are mutated (underlined) to abolish binding.
For the transient transfection assays we used 3U104 NIH-3T3 cells
per well in 24 well plates from Nunc Inc. To each well of cells were
added 2.5 ng pRL-CMV vector from Promega as internal standard,
400 ng reporter DNA, the indicated amount of e¡ector DNA
(pCMV4-Nkx6.1 (1.4 kb) (see below) or pCMV4-Nkx6.1HD/
VP16AD), and ¢lled up with empty pCMV4 vector to a total of
500 ng DNA per well. The DNA was incubated for 45 min at room
temperature with 3 Wl LipofectAMINE in 50 Wl OptiMEM from Gib-
co-BRL, added to the cells and incubated. Then the cells were culti-
vated for 36 h, harvested and assayed for ¢re£y and Renilla luciferase
activity using the Dual-Luciferase Reporter Assay System from Prom-
ega.
2.9. Stable transfection of MSL-G-AN cells
For the stable expression of Nkx6.1 in the MSL-G-AN cells most
of the long UTRs of the 3211 bp Nkx6.1 cDNA sequence were re-
moved at the unique restriction sites FspI and ApaLI. The resulting
Nkx6.1 cDNA piece of 1456 bp was blunt end ligated into the EcoRV
site of the pBluescript SK II vector from Stratagene and then in-
serted in the correct orientation at the HindIII and XbaI sites of the
pCMV4 vector [13]. 2U108 MSL-G-AN cells were resuspended in 500
Wl 1UPBS with 40 Wg pCMV4-Nkx6.1 (1.4 kb) and 10 Wg ploxPneo-1
vector (a kind gift from A. Nagy) conferring resistance to Geneticin
(antibiotic G418 sulphate) from Gibco-BRL. The cells were electro-
porated as described [15] except that the cells were transferred to a 14
cm dish and cultivated for 24 h in normal medium before selection in
medium containing 200 Wg/ml G418. After 1 week the selection me-
dium contained 100 Wg/ml G418 until G418-resistant single cells had
grown to form colonies. Eleven clones were isolated and cultivated
separately. In vivo passage and reestablishment as cell lines was per-
formed as described [16,17].
For RNA isolation 1U107 cells was extracted with 1 ml RNAzol B
from Campro Scienti¢c as described by the manufacturer. cDNA syn-
thesis was carried out in 25 Wl reactions as described [4]. Multiplex
RT-PCR was performed as described in [4]. Twenty-¢ve cycles of
PCR were run for Nkx6.1 (284 bp) and G6PDH (214 bp), and 22
cycles were run for insulin (312 bp) and G6PDH (214 bp).
Nuclear extracts were prepared from 2U108 cells as described in
[18] except that PMSF was replaced with AEBSF. Western blot anal-
ysis to test the Nkx6.1 protein levels in the clones was performed as
described [14].
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2.10. Cell lines
COS7 cells were cultivated in DMEM 4500 mg/l glucose, NIH-3T3
cells in DMEM 1000 mg/l glucose, both media containing 10% foetal
bovine serum, 100 U/ml penicillin and 100 Wg/ml streptomycin. MSL-
G-AN cells were established and cultivated as described [17], NHI-6F-
INS cells as described [16], and the AN+Pdx1 clone 1.1.10 as de-
scribed [19]. All cell lines were kept in humidi¢ed incubators with
5% CO2 at 37‡C.
2.11. Immunocytochemical stainings and antibodies
Immunocytochemical stainings of monolayer cells were carried out
with the Histostain-Plus kit from Zymed Laboratories Inc. Monoclo-
nal antibodies against insulin (HUI-18) and glucagon (GLU-001) were
from Novo-Nordisk Biolabs. A series of eight di¡erent antisera (1852^
1859) were raised against a GST-Pdx1 fusion protein [19,20]. Rabbit
antisera against Nkx6.1 were described in [4]. For immunocytochem-
istry K-Nkx6.1-174 and K-Pdx1-1856 were used. EMSA supershift
antisera: K-Nkx6.1-173, K-Pdx1-1852. Western blot antiserum: K-
Nkx6.1-173.
3. Results
3.1. Isolation and in vitro expression of the rat Nkx6.1 cDNA
Using primers derived from the hamster Nkx6.1 sequence a
220 bp fragment of the 3P-end of the coding sequence was
PCR ampli¢ed from rat islet cDNA. This fragment was
used as a probe in a high stringency colony hybridisation
screening of a cDNA library made from growth hormone-
stimulated newborn rat islets [12]. A 3211 bp cDNA contain-
ing a 1095 bp open reading frame that matched the hamster
Nkx6.1 sequence was isolated. The insert contained 788 bp 5P-
UTR and 1328 bp 3P-UTR. In the 5P-UTR 311 bp upstream
of the predicted translation start codon another ‘ATG’ codon
is found, but this is closely followed by a termination codon
and would give rise to a polypeptide no longer than six amino
acid residues (Fig. 1). The predicted 365 amino acid rat
Nkx6.1 peptide sequence deviates by only 11 and six amino
acid residues from the human and the hamster homologues,
respectively (Fig. 2). The homeodomain sequences are identi-
cal between the three mammalian species and so are the NK
decapeptides except for an asparagine in the human sequence
where the rat and the hamster sequences have aspartate (Fig.
2).
Notably, [35S]methionine labeling by in vitro transcription
Fig. 1. The 3211 bp rat Nkx6.1 nucleotide sequence and the de-
duced amino acid sequence (GenBank accession number AF004431).
The 788 bp 5P-UTR is followed by the 1095 bp coding region pre-
dicted to be translated into a 365 amino acid peptide sequence. The
3P-UTR consists of 1328 bp. The ‘ATG’ codon found 311 bp up-
stream of the long open reading frame is underlined.
Fig. 2. A ClustalW alignment of the rat Nkx6.1 peptide sequence
with the hamster, the human and the chicken (the sequence is from
a partial clone) homologues. The mouse sequence of Nkx6.2/Gtx is
also included. Identical positions are marked with black boxes and
conservative substitutions are boxed in grey. The homeodomain is
underlined with a black bar and the conserved NK decapeptide se-
quence is underlined with a grey bar. The Nkx6.2/Gtx sequence is
closely related to Nkx6.1 and di¡ers primarily in the lack of the
long N-terminal serine and alanine stretches.
Fig. 3. A: In vitro transcribed and translated 35S-labeled Nkx6.1 an-
alysed by SDS-PAGE and autoradiographed. Lane 1: control reac-
tion without DNA template. Lane 2: the labeled Nkx6.1 product
migrates as a double band with molecular weights of approximately
39 and 42 kDa, the latter being strongest in intensity. B: Western
blot with K-Nkx6.1 primary antiserum. Lane 1: the Nkx6.1-express-
ing NHI-6F-INS insulinoma cell line (positive control). Lane 2:
Nkx6.1-transfected COS7 cells. Lane 3: COS7 cells (negative con-
trol).
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and translation of the isolated cDNA resulted in two products
with approximate molecular weights of 42 and 39 kDa (Fig.
3A). Using an K-Nkx6.1 antiserum [4] we performed Western
blot analysis of COS7 cells transfected with the isolated
Nkx6.1 cDNA. As seen in Fig. 3B two bands of molecular
weights 42 and 39 kDa were detected, con¢rming the result
obtained by [35S]methionine labeling.
3.2. Nkx6.1 binds a speci¢c DNA consensus sequence
In order to identify the optimal DNA-binding sequence for
Nkx6.1, a glutathione S-transferase Nkx6.1 homeodomain
(GST-Nkx6.1HD) fusion protein was synthesised and used
in a PCR-based binding site selection on randomised synthetic
oligonucleotides. Two independent experiments (called A and
B) of ¢ve cycles of selection were performed in parallel and as
shown in Fig. 4A the binding a⁄nities increased markedly for
each cycle. Finally, the resulting oligonucleotides were cloned
and 48 colonies from both selection A and B were randomly
picked and the inserts sequenced. Every single insert con-
tained at least one TAAT motif. In experiment A a total of
120 TAAT sequences were identi¢ed giving an average of
approximately three per insert, and the result of the alignment
including the four £anking nucleotides at either side is shown
in Fig. 4B. Experiment B gave a very similar result (Fig. 4B),
and the deduced DNA-binding site consensus sequence for
Nkx6.1 obtained in vitro is TTAATTG/A.
A number of the selected sequences were tested for binding
to GST-Nkx6.1HD and as exempli¢ed in Fig. 4C they show
di¡erent binding a⁄nities depending on how closely the se-
quences match the consensus and also depending on the num-
ber of binding sites they contain. The strongest binding se-
quence is A45, which contains two perfect consensus binding
sites, whereas A37 with only one TAAT motif and no £anking
nucleotides that match the consensus is a poor binder. Other
strong binding sequences are A33 (which is identical to A45),
A20 and B11 which also contain two closely matching binding
sites, and B26 with one perfectly matching Nkx6.1-binding
site.
To test the authenticity of the selected binding site consen-
sus sequence, nuclear extracts from glucagonoma cells stably
expressing Nkx6.1 (see below) were used in an EMSA with the
A45 sequence as probe. This con¢rmed that TTAATTG is a
binding site for the exogenously expressed full-length Nkx6.1
protein, which forms complexes with the A45 probe recog-
nised by the K-Nkx6.1 antiserum (Fig. 5). Another L-cell ho-
meodomain factor, Pdx1, also binds the A45 probe (Fig. 5).
Binding of Pdx1 is not surprising given the close resemblance
of the A45 binding sequence TTAATTG to the canonical
Pdx1 binding site C/TTAATG [21,22]. EMSA analysis with
mutated binding sites showed that the nucleotides £anking the
TAAT core sequence are important for optimal binding of
full-length Nkx6.1 (data not shown).
Fig. 4. A: The binding a⁄nity of GST-Nkx6.1HD to the oligonucleotide pool (indicated by the arrow) increased for each cycle of binding site
selection. Oligonucleotides that had been selected for binding to GST-Nkx6.1HD were PCR ampli¢ed and used as probes in an EMSA with
5 ng GST-Nkx6.1HD per lane. Lane B1: experiment B after one cycle of selection. Lane B2: experiment B after two cycles of selection and so
forth. A similar result was obtained for experiment A. B: Alignment of all the TAAT motifs and the four £anking nucleotides at either side of
the sequences selected for binding to GST-Nkx6.1HD. The results of the two independent experiments A and B were very similar. The DNA-
binding site consensus sequence for Nkx6.1 is TTAATTG/A. C: Di¡erent binding site selected sequences were PCR ampli¢ed and show di¡er-
ent binding a⁄nities to 5 ng GST-Nkx6.1HD in an EMSA. Lanes 1^5: sequences from experiment A. Lanes 6^11: sequences from experiment
B. Lane 12: control PCR without template. Lane 13: the randomised (N20) oligonucleotide, BSS1.
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3.3. Transactivating e¡ect of Nkx6.1HD/VP16AD fusion
construct
To investigate if the binding of Nkx6.1 to the isolated con-
sensus sequence could take place in an in vivo-like situation,
we set up a transfection experiment in NIH-3T3 cells. Here
the transactivation ability of a chimeric protein with the
Nkx6.1 homeodomain sequence fused to the VP16 activation
domain (Nkx6.1HD/VP16AD) was tested on a reporter plas-
mid containing four copies of the selected Nkx6.1-binding site
(TTAATTG) inserted in front of the TK promoter. As a
control an equivalent TK promoter with four mutated
Nkx6.1-binding sites (TTCCTTG) inserted at the same posi-
tion was used.
The TK promoter sequence itself was subsequently identi-
¢ed to contain two TAAT motifs (GTAATAT and TTAA-
TAT) which bind the Nkx6.1HD with some but not optimal
a⁄nity. Consequently, the Nkx6.1HD/VP16AD activates the
TK promoter to some extent (7^10-fold), and the induction
level of the TK promoter alone with no inserts is similar to
the induction level for the TK promoter with the mutated
binding sites inserted (data not shown). However, when four
copies of the Nkx6.1 binding site are inserted in front of the
Fig. 6. The TTAATTG sequence functions as a binding site for Nkx6.1HD in a transient transfection experiment in NIH-3T3 cells. Four
TTAATTG Nkx6.1-binding sites were inserted in front of the TK promoter driving the luciferase reporter gene. The control had four mutated
Nkx6.1-binding sites (TTCCTTG) inserted at the same position. Full-length Nkx6.1 is not capable of a¡ecting the TK promoter activity,
whereas the Nkx6.1HD/VP16AD fusion construct activates both reporters due to two TAAT motifs within the TK promoter sequence. The in-
duction of the promoter with the four Nkx6.1-binding sites is twice as strong as the induction of the control promoter with the mutated sites.
The average of three independent experiments is presented, error bars indicate S.E.M.
Fig. 5. Full-length Nkx6.1 binds the TTAATTG sequence. However,
another homeodomain factor, Pdx1, can also bind this probe.
EMSA with 5 Wg nuclear extracts (NE) from MSL-G-AN cells, a
stable Pdx1-expressing MSL-G-AN clone, and a stable Nkx6.1-ex-
pressing MSL-G-AN clone. Supershifts with the antisera (Ab) K-
Pdx1 and K-Nkx6.1. PI: preimmune serum. Probe: double-stranded
32P-labeled A45.A (containing two TTAATTG sites).
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TK promoter, the activation is approximately 20-fold (Fig. 6).
This shows that the TTAATTG sequence is recognised by the
Nkx6.1HD in an in vivo context. In a similar experiment full-
length Nkx6.1 is not capable of activating the TK promoter
(Fig. 6).
3.4. Screening for potential Nkx6.1 target genes
To further investigate the function of Nkx6.1, the Nkx6.1
cDNA under transcriptional control of the CMV promoter
was used to stably transfect an in vitro culture of MSL-G-
AN tumour cells, an Nkx6.1-negative rat K-cell line that
forms glucagonomas when passaged subcutaneously in rats
[17,23]. Eleven G418-resistant MSL-G-AN clones were iso-
lated. Four clones (clones 3, 4, 9 and 10) expressed high levels
of Nkx6.1 protein (Fig. 7A) and these were chosen for further
analysis. As control cells we used untransfected MSL-G-AN
and the Nkx6.1-negative clone 2 (Fig. 7A,B).
Empirically we know that the MSL-G-AN cells can lose
their hormone expression solely because of prolonged in vitro
cultivation, so the clones were grown in vivo as tumours in
rats [17], and were subsequently screened by multiplex RT-
PCR for changes in transcription of a number of islet cell-
speci¢c genes. We did not observe any changes in the expres-
sion level of the hormones glucagon, somatostatin and IAPP,
but after the in vivo passage a small percentage (V1%) of the
cells had become insulin-positive in all the Nkx6.1-positive
clones 3, 4, 9 and 10 but not in the Nkx6.1-negative clone 2
nor in MSL-G-AN cells (Figs. 7B and 8). The expression of
the L-cell factors Pax4, Pdx1, GLUT2 and GLP-1-R was not
induced by the presence of Nkx6.1 in these clones, and the
expression level of other important islet cell factors such as
CCK, Pax6, Nkx2.2, Isl1, NeuroD, HNF1K, HNF4K, gluco-
kinase and Brn4 was not a¡ected (data not shown). Double
immuno£uorescent stainings con¢rmed the absence of Pdx1
immunoreactivity in the insulin-producing sub-population
(data not shown).
4. Discussion
Here we have cloned the rat Nkx6.1 cDNA sequence, iden-
ti¢ed the DNA-binding site to be TTAATTG/A and shown
that it is recognised in vivo by the Nkx6.1 homeodomain
when present in a reporter plasmid. This is in agreement
with the recent ¢nding that Nkx6.2, which has a homeodo-
main sequence almost identical to Nkx6.1, binds with high
a⁄nity to a TAATTA sequence [24]. Nkx6.2 was initially
shown to bind a MEF-2 motif (CTAAAAATAAC), which
is the binding site for serum response factor-related proteins
(RSRFs). Therefore Nkx6.2 was hypothesised to be a tran-
scriptional repressor of serum-induced genes by competing
with the RSRFs for binding to the same sites [6]. Despite
the high degree of sequence identity between the homeodo-
mains of Nkx6.1 and Nkx6.2, we have not been able to detect
Nkx6.1 binding to the MEF-2 motif (M.C. JÖrgensen, unpub-
lished observation).
For most homeodomain factors a TAAT motif is the core
sequence essential for binding to DNA (reviewed in [25]). One
of the few exceptions is Nkx2.1, which preferentially binds a
CAAG core [26]. By systematically combining di¡erent amino
acid residue substitutions in the helix III and the N-terminal
arm of the Nkx2.1 homeodomain with point mutations of the
DNA-binding site, it was shown that particularly the amino
acid residues 6, 7, 8, 50, 51 and 54 of the homeodomain
sequence interact closely with the speci¢c bases of the core
nucleotide sequence [27]. It was thus shown that amino acids
Q6, T7 and Y8 in the N-terminal end of the Antennapedia
homeodomain would dictate the 5P-T in the core motif
(TAAT), whereas V6, L7 and F8 found in the Nkx2.1 homeo-
domain dictate a C at that site (CAAG). The 3P-A (TAAT) is
speci¢ed by amino acid residue 51 which is the most con-
served among all homeodomains (almost always N), and
M54 in the Antennapedia homeodomain would dictate the
3P-T in the core sequence (TAAT), whereas the Nkx2.1
homeodomain Y54 prefers a G at that position (CAAG).
Finally, it was shown that the two nucleotides immediately
3P of the TAAT core (TAATNN) are speci¢ed by amino
acid residue 50. Thus, K50 in the bicoid homeodomain dic-
tates CC at those sites, whereas Q50 in the Nkx2.1 homeo-
domain dictates TG. Based on our selected binding site, the
N-terminal amino acids P6, T7 and F8 in the Nkx6.1 homeo-
domain sequence appear to prefer a T in the most 5P position
of the core motif (TAAT). Similarly, T54 in the Nkx6.1HD
seems to prefer a T at the most 3P position of the core
(TAAT). The N51 and Q50 amino acids in the Nkx6.1
homeodomain are consistent with the nucleotides A found
Fig. 7. A: Western blot analysis of the Nkx6.1 protein levels in the
MSL-G-AN clones. B: Multiplex RT-PCR analysis showing induc-
tion of insulin expression in Nkx6.1-positive clones after in vivo
passage.
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at position 3 and TG found at the 3P £anking positions of the
core in the selected sequence (TTAATTG/A).
In general, homeodomain proteins are known to interact
with DNA with relatively low binding speci¢city compared
to other classes of transcription factors (reviewed in [28]).
As a consequence they do not show much binding speci¢city
in vitro and bind indiscriminately to many TAAT-containing
sequences. Increased speci¢city is often accomplished in vivo
by co-operative binding with one or more cofactors [29]. An
example of this is the complexes formed between Pbx and
Prep proteins and members of the Hox family of HD proteins
[30]. Notably, the sequence selected by the Nkx6.1HD is also
recognised by Pdx1, another homeodomain protein important
for pancreas development and L-cell function [10,31,32]. Ab-
sence of Nkx6.1 or Pdx1, which are co-expressed during most
of the pancreatic development [2], have very di¡erent conse-
quences for pancreas development (M. Sander, personal com-
munication, [31,32]), suggesting that these proteins regulate
distinct target genes. This question could be addressed by
the use of di¡erent cofactors to achieve di¡erent DNA-bind-
ing speci¢cities between the two proteins. Indeed, Pdx1 forms
distinct cell type-speci¢c complexes with Meis and Pbx pro-
teins [33,34]. Such a scenario might make it di⁄cult to identify
the direct target genes for a homeodomain factor like Nkx6.1
based on in vitro selected binding sites. A new family of ho-
meodomain-interacting protein kinases (HIPKs) has recently
been identi¢ed, and HIPK2 was shown to enhance the DNA-
binding activity of Drosophila NK-3 and thereby act as a co-
repressor of NK-3 autorepression of its own promoter [35].
Potentially the HIPKs could be possible cofactor candidates
for Nkx6.1 if they are expressed in the L-cells.
It has been suggested that Nkx6.1 could be a repressor of
glucagon expression [10] and the glucagon promoter sequence
contains a perfect Nkx6.1 consensus binding site at position
3492 to 3486 relative to the translational start site. However,
in the stable Nkx6.1-expressing MSL-G-AN clones, we found
the glucagon expression level unchanged after in vivo passage.
Consistent with this, Nkx6.1-expressing KTC1.9 cells [1] show
a high glucagon expression level. In transient transfection
studies we have tested the e¡ect of Nkx6.1 on the glucagon
and insulin promoters, but failed to detect any e¡ect on the
transcriptional activities of these promoters in both islet and
non-islet cell lines (M.C. JÖrgensen, unpublished observa-
tions). Nevertheless, expression of Nkx6.1 in the MSL-G-
AN cells combined with in vivo culture causes the induction
of insulin in a sub-population of the cells, suggesting that
Nkx6.1 can induce insulin production possibly by an indirect
mechanism. The limited number of cells that produce insulin
could re£ect heterogeneity of the MSL-G-AN cells, where the
presence of Nkx6.1 is su⁄cient in only a sub-population of
the cells to trigger the shift towards a L-cell-like phenotype. In
contrast to Nkx6.1, Pdx1 is su⁄cient to induce insulin pro-
duction in MSL-G-AN cells without the need for an in vivo
culture step [19]. However, we were not able to detect Pdx1
Fig. 8. Insulin production in Nkx6.1-expressing MSL-G-AN cells. Immunoperoxidase stainings of Nkx6.13 (clone 2), Nkx6.1 (clone 10),
Pdx1 (clone 1.1.10) AN cells, and NHI-6F-INS cells with the indicated antisera. The Nkx6.1-expressing AN clones show induction of insulin
expression in a subset of the cells (indicated by the arrow), whereas the glucagon expression levels are una¡ected. The K-Nkx6.1 and K-Pdx1
antisera give distinct red nuclear stainings, whereas the K-insulin and K-glucagon antibody stainings (also in red) are cytoplasmic.
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expression in Nkx6.1-transfected AN cells after in vivo culture
suggesting either that transient expression of Pdx1 occurs or
that a Pdx1-independent pathway of insulin gene activation is
operating in these cells.
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